A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2018
At a glance
- Drugs AGN-242071 (Primary) ; Donepezil; Memantine
- Indications Alzheimer's disease
- Focus Adverse reactions; Diagnostic use; Pharmacokinetics; Therapeutic Use
- Sponsors Allergan
- 31 Oct 2018 Status changed from recruiting to withdrawn prior to enrolment due to Business decision.
- 14 Aug 2018 Planned initiation date (Estimated date of first participant enrolled) changed from 30 Jul 2018 to 30 Sep 2018.
- 14 Aug 2018 Status changed from not yet recruiting to recruiting.